Myd88

Splenic B cells were purified by negative selection using CD43 beads (Miltenyi Biotec). Purified B cells were cultured in media, 10 μg/ml F(ab′)₂ fragment of anti-mouse IgM (Jackson ImmunoResearch), 10 μg/ml LPS, 5 μg/ml CpG, or 10 μg/ml Pam3CSK4 (InvivoGen) at 37 °C for the indicated times. In some experiments, the cells were pre-treated with different concentrations of the inhibitors U0126, LY294002 (Cell Signaling Technology), NSC668394, SB203580 (Calbiochem), or PS1145 (Sigma-Aldrich) for 1 hour before stimulating with LPS. Lysates were prepared and immunoblotting performed as described (9 (link), 11 (link)). All immunoblotting antibodies were from Cell Signaling Technology, except for IκB, actin (Santa Cruz Biotechnology, Inc.) and ezrin (EMD Millipore). PMA (50 ng/ml) and ionomycin (500 ng/ml) (Sigma-Aldrich) were used to stimulate B cells ex vivo 1.5 h after in vivo LPS injection. siRNAs to ezrin, MyD88, TRIF, IRF3, and control siRNAs (Dharmacon) were used at 2 μM according to manufacturer’s instructions and as described previously (14 (link)).

N/TERTs, an immortalized KC cell line (Dickson et al., 2000 (link)), was grown in Keratinocyte-serum-free medium (17005-042, Thermo Fisher Scientific, Waltham, MA) supplemented with 30 μg/ml bovine pituitary extract, 0.2 ng/ml EGF, and 0.3 mM calcium chloride. Cells at proper confluency were subsequently treated with recombinant human IL-1β (10 ng/ml, R&D Systems, Minneapolis, MN), IL-36γ (10 ng/ml, R&D Systems), and TNF (10 ng/ml, R&D Systems) for the indicated time before RNA or protein extraction.
siRNA targeting IRAKs, including IRAK2 (Accell Human IRAK2 siRNA, E-004761-00-0010), IRAK1 (E-004760-00-0010), and IRAK4 (E-003302-00-0010); ZNF750 (E-014417-00-0010); IL1R (E-005188-00-0005); MYD88 (E-004769-00-0005); and control siRNA (D-001910-01-20) were purchased from Dharmacon company (Lafayette, CO) and introduced into cells by Delivery medium (B-005000-100, Dharmacon) according to the manufacturer’s instructions.